Denmark · Delayed Price · Currency is DKK H. Lundbeck Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw strong revenue and profit growth, driven by VYEPTI and REXULTI, successful partner market transitions, and pipeline progress. Upgraded guidance reflects robust fundamentals, delayed generic competition, and disciplined capital allocation.
-
Record revenues and profitability were achieved in 2025, with strong growth in strategic brands and a robust pipeline. The board and executive team were re-elected, a new member with neuroscience expertise joined, and all proposals—including a 21% dividend increase—were approved.
Fiscal Year 2025
-
A focused neuroscience strategy, capital reallocation, and a simplified commercial model have driven strong growth, with VYEPTI and REXULTI as key assets. A diversified, innovation-driven pipeline and dynamic investment approach support upgraded financial guidance and long-term ambitions.
-
Double-digit revenue and profit growth in the first nine months of 2025 were driven by Vyepti and Rexulti, leading to upgraded full-year guidance. Strategic pipeline advances and commercial restructuring support long-term growth, despite FX and generic headwinds.
-
Strategic brands drove 21% growth and revenue rose 15% year-over-year, prompting upgraded guidance for both revenue and Adjusted EBITDA. Vyepti and Rexulti led performance, while pipeline and capital reallocation support long-term growth.
-
Q1 2025 saw 16% revenue growth and 24% rise in strategic brands, led by Vyepti and Rexulti. Full-year guidance was raised, reflecting strong demand, robust pipeline progress, and disciplined capital allocation, despite anticipated generic competition and portfolio erosion.
-
The AGM highlighted record financial results, a 36% dividend increase, and a strategic focus on rare neurological diseases through acquisitions and pipeline expansion. All board proposals were adopted, and key risks around R&D and market conditions were discussed with shareholders.
-
Significant progress was reported on growth, pipeline transformation, and financial discipline, with four late-stage assets and a robust commercial engine driving mid- and long-term outlook. Major acquisitions and focused R&D investment underpin a news-rich pipeline and sustainable growth strategy.
Fiscal Year 2024
-
2024 delivered record revenue and double-digit growth in strategic brands, with robust pipeline progress and a major acquisition. 2025 guidance anticipates continued strong growth, margin stability despite higher R&D, and resilience to competitive and generic pressures.
-
Revenue grew 13% year-over-year, led by 21% growth in strategic brands, with Vyepti and Rexulti as key drivers. The company raised its full-year guidance, reported strong cash flow, and is preparing for the Longboard acquisition, which will shift its net cash to net debt.
-
Focused innovation and capital reallocation are driving double-digit growth in strategic brands and transforming the pipeline, with four phase III programs expected by 2026. Financial guidance is raised, targeting mid-single-digit CAGR and a 30%-32% EBITDA margin, supported by the largest capital allocation program in company history.
-
The acquisition of Longboard Pharmaceuticals brings a de-risked, late-stage asset with breakthrough therapy designation for rare epilepsies, supporting long-term growth and a focused innovator strategy. The $2.5 billion deal is expected to close by year-end, with peak sales potential of $1.5–2 billion, mainly from the U.S.
-
Double-digit revenue growth and strong strategic brand performance led to raised 2024 guidance. Vyepti, Rexulti, and Brintellix/Trintellix drove results, with robust pipeline progress and a strengthened net cash position.